These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 12462286

  • 21. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms.
    Lanier BQ, Gross RD, Marks BB, Cockrum PC, Juniper EF.
    Ann Allergy Asthma Immunol; 2001 Jun; 86(6):641-8. PubMed ID: 11428736
    [Abstract] [Full Text] [Related]

  • 22. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
    Fujishima H, Ohashi Y, Takamura E.
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
    [Abstract] [Full Text] [Related]

  • 23. Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: a real-world comparison of efficacy and ocular comfort.
    Ganz M, Koll E, Gausche J, Detjen P, Orfan N.
    Adv Ther; 2003 Oct; 20(2):79-91. PubMed ID: 12836808
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
    Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G.
    Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
    [Abstract] [Full Text] [Related]

  • 25. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS.
    Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye.
    Mah FS, O'Brien T, Kim T, Torkildsen G.
    Curr Med Res Opin; 2008 Feb; 24(2):441-7. PubMed ID: 18167176
    [Abstract] [Full Text] [Related]

  • 29. One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears.
    Abelson MB, Pratt S, Mussoline JE, Townsend D.
    Clin Ther; 2003 Jul; 25(7):2070-84. PubMed ID: 12946551
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate.
    Aguilar AJ.
    Acta Ophthalmol Scand Suppl; 2000 Jul; (230):52-5. PubMed ID: 11057352
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
    Leonardi A, Abelson MB.
    Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
    Abelson MB, Lanier RQ.
    Acta Ophthalmol Scand Suppl; 1999 Oct; (228):53-6. PubMed ID: 10337434
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis.
    Abelson MB, Gomes PJ, Vogelson CT, Pasquine TA, Turner FD, Wells DT, Robertson SM.
    Curr Med Res Opin; 2005 May; 21(5):683-91. PubMed ID: 15969867
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.